Imaging studies - Differential action of typical and atypical antipsychotics in a network perspective

Pharmacopsychiatry

Volumn 41, Issue SUPPL. 1, 2008, Pages

  Vernaleken, I ^a   Cumming, P ^b   Grunder G ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 (7 BENZOFURANYL) 8 CHLORO 2,3,4,5 TETRAHYDRO 7 HYDROXY 3 METHYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBON 11; CLOZAPINE; DOPA; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; FLUORODEOXYGLUCOSE F 18; GLUTAMIC ACID; HALOPERIDOL; MELPERONE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIPAMPERONE; QUETIAPINE; RACLOPRIDE; RISPERIDONE; SERTINDOLE; VOLINANSERIN; ZIPRASIDONE;

BASAL GANGLION; BRAIN CORTEX; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DRUG BINDING; DRUG MECHANISM; GABAERGIC SYSTEM; HUMAN; HYPOTHESIS; MOLECULAR IMAGING; NERVE CELL NETWORK; NEUROTRANSMISSION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOSIS; RECEPTOR BLOCKING; RECEPTOR OCCUPANCY; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC NERVE CELL; SEROTONINERGIC SYSTEM; THALAMUS;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; DIAGNOSTIC IMAGING; DOPAMINE; HUMANS; MODELS, BIOLOGICAL; NEURAL PATHWAYS; NEURONS; SCHIZOPHRENIA;

EID: 54749094348     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1082058     Document Type: Review

References (108)

1. Aalto S, Hirvonen J, Kajander J et al. Ketamine does not decrease striatal dopamine D2 receptor binding in man. Psychopharmacology 2002; 164: 401-406
2. Abi-Dargham A, Gil R, Krystal J et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiat 1998; 155: 761-767
3. Abi-Dargharn A, Rodenhiser J, Printz D et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 2000; 97: 8104-8109
4. Abi-Dargham A, Mawlawi O, Lombardo I et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 2002; 22: 3708-3719
5. Agid O, Mamo D, Ginovart N et al. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response - a double-blind PET study in schizophrenia. Neuropsychopharmacology 2007; 32: 1209-1215
6. Andreasen NC. A unitary model of schizophrenia: Bleuler's "fragmented phrene" as schizencephaly. Arch Gen Psychiat 1999; 56: 781-787
7. Bäumler H. Veränderungen des Thalamus bei Schizophrenie. Journal für Himforschung 1954; 1: 156-169
8. Bartlett EJ, Brodie JD, Simkowitz P et al. Effects of haloperidol challenge on regional cerebral glucose utilization in normal human subjects. Am J Psychiat 1994; 151: 681-686
9. Bartlett EJ, Brodie JD, Simkowitz P et al. Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients. Am J Psychiat 1998; 155: 337-343
10. Bortolazzi A, Diaz-Mataix L, Scorza MC, Celada P, Artigas F. The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity. J Neurochem 2005; 95: 1597-1607
11. Braus DF, Weber-Fahr W, Tost H, Ruf M, Henn FA. Sensory information processing in neuroleptic-naive first-episode schizophrenic patients: a functional magnetic resonance imaging study. Arch Gen Psychiat 2002; 59: 696-701
12. 123I]epidepride SPET study of amisulpride-treated patients. Am J Psychiat 2003; 160: 1413-1420
13. Brown RM, Crane AM, Goldman PS. Regional distribution of monoamines in the cerebral cortex and subcortical structures of the rhesus monkey: concentrations and in vivo synthesis rates. Brain Research 1979; 168: 133-150
14. Buchsbaum MS, Someya T, Teng CY et al. PET and MRI of the thalamus in never-medicated patients with schizophrenia. Am J Psychiat 1996: 153: 191-199
15. Buchsbaum MS, Christian BT, Lehrer DS et al. D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophrenia Research 2006; 85: 232-244
16. Buchsbaum MS, Haznedar MM, Aronowitz J et al. FDG-PET in never-previously medicated psychotic adolescents treated with olanzapine or haloperidol. Schizophrenia Research 2007; 94: 293-305
17. Byne W, Buchsbaum MS, Mattiace LA et al. Postmortem assessment of thalamic nuclear volumes in subjects with schizophrenia. Am J Psychiat 2002; 159: 59-65
18. Carlsson A. Speculations on the control of mental and motor functions by dopamine-modulated cortico-striato-thalamo-cortical feedback loops. The Mount Sinai J Med, New York 1988; 55: 6-10
19. Carlsson A, Waters N, Carlsson ML. Neurotransmitter interactions in schizophrenia-therapeutic implications. Eur Arch Psychiat Clin Neurosci 1999; 249 (Suppl 4): 37-43
20. Carlsson A. The neurochemical circuitry of schizophrenia. Pharmacopsychiatry
21. Crespo-Facorro B, Paradiso S, Andreasen NC et al. Recalling word lists reveals "cognitive dysmetria" in schizophrenia: a positron emission tomography study. Am J Psychiat 1999; 156: 386-392
22. Csomor PA, Stadler RR, Feldon J et al. Haloperidol differentially modulates prepulse inhibition and p50 suppression in healthy humans stratified for low and high gating levels. Neuropsychopharmacology 2008; 33: 497-512
23. Cullen TJ, Walker MA, Parkinson N et al. A postmortem study of the mediodorsal nucleus of the thalamus in schizophrenia. Schizophrenia Research 2003; 60: 157-166
24. Deakin JF, Lees J, MacKie S et al. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch Gen Psychiat 2008; 65: 154-164
25. Deep P, Dagher A, Sadikot A, Gjedde A, Cumming P. Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine. Synapse 1999; 34: 313-318
26. Pietro NC Di, Seamans JK. Dopamine and serotonin interactions in the prefrontal cortex: insights on antipsychotic drugs and their mechanism of action. Pharmacopsychiatry 2007; 40 (Suppl 1): S27-33
27. Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci 2001; 24: 31-55
28. Fajolles C, Boireau A, Ponchant M, Laduron PM. 3 H]RP 62203, a ligand of choice to label in vivo brain 5-HT-2 receptors. Eur J Pharmacol 1992; 216: 53-57
29. Farde L, Nordström AL, Wiesel FA et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiat 1992; 49: 538-544
30. Frankle WG. Neuroreceptor imaging studies in schizophrenia. Harvard Rev Psychiat 2007; 15: 212-232
31. Fünfgeld E. ber histologische Unterschungen des Thalamus bei Katatonie. Klinische Wochenschrift 1924; 3: 69-70
32. Gaffan D, Parker A. Mediodorsal thalamic function in scene memory in rhesus monkeys. Brain 2000; 123 (Pt 4): 816-827
33. Gallinat J, Obermayer K, Heinz A. Systems Neurobiology of the Dysfunctional Brain: Schizophrenia. Pharmacopsychiatry 2007; 40: S40-S44
34. Gefvert O, Lundberg T, Wieselgren IM et al. D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur Neuropsychopharmacol 2001; 11: 105-110
35. Gefvert O, Lindstrom LH, Waters N et al. Different corticostriatal patterns of L-DOPA utilization in patients with untreated schizophrenia and patients treated with classical antipsychotics or clozapine. Scand J Psychol 2003; 44: 289-292
36. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 2001; 156: 117-154
37. Goldsmith SK, Shapiro RM, Joyce JN. Disrupted pattern of D2 dopamine receptors in the temporal lobe in schizophrenia. A postmortem study. Arch Gen Psychiat 1997; 54: 649-658
38. Gründer G, Yokoi F, Offord SJ et al. Time course of 5-HT2A receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography. Neuropsychopharmacology 1997; 17: 175-185
39. Gründer G, Landvogt C, Vernaleken I et al. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology 2006; 31: 1027-1035
40. 18F]Fallypride PET Study. Am J Psychiat 2008
41. Gulledge AT, Jaffe DB. Dopamine decreases the excitability of layer V pyramidal cells in the rat prefrontal cortex. J Neurosci 1998; 18: 9139-9151
42. 125I]epidepride. Synapse 1996; 23: 115-123
43. Hazlett EA, Buchsbaum MS, Kemether E et al. Abnormal glucose metabolism in the mediodorsal nucleus of the thalamus in schizophrenia. Am J Psychiat 2004; 161: 305-314
44. Hernandez LF, Segovia G, Mora F. Effects of activation of NMDA and AMPA glutamate receptors on the extracellular concentrations of dopamine, acetylcholine, and GABA in striatum of the awake rat: a microdialysis study. Neurochemical Research 2003; 28: 1819-1827
45. Hietala J, Syvalahti E, Vuorio K et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 1995; 346: 1130-1131
46. Hirvonen J, Erp TG van, Huttunen J et al. Brain dopamine d1 receptors in twins discordant for schizophrenia. Am J Psychiat 2006; 163: 1747-1753
47. Holcomb HH, Cascella NG, Thaker GK et al. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. Am J Psychiat 1996; 153: 41-49
48. Huber G. Pneumencephalographische und psychopathologische Bilder bei endogenen Psychosen. Berlin, Göttingen, Heidelberg: Springer; 1957
49. Hurlemann R, Matusch A, Kuhn KU et al. 5-HT2A receptor density is decreased in the at-risk mental state. Psychopharmacology 2008; 195: 579-590
50. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiat 1999; 156: 286-293
51. Kargieman L, Santana N, Mengod G, Celada P, Artigas F. Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine. Proc Natl Acad Sci USA 2007; 104: 14843-14848
52. Karlsson P, Farde L, Halldin C, Sedvall G. PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am J Psychiat 2002; 159: 761-767
53. Kim JJ, Kim DJ, Kim TG et al. Volumetric abnormalities in connectivity-based subregions of the thalamus in patients with chronic schizophrenia. Schizophrenia Research 2007; 97: 226-235
54. 18F]fluorodopa/positron emission tomography study. J Neurosci 2007; 27: 8080-8087
55. Laruelle M, Abi-Dargham A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol 1999; 13: 358-371
56. Lawler CP, Prioleau C, Lewis MM et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999; 20: 612-627
57. Lawrie SM, Whalley HC, Abukmeil SS et al. Brain structure, genetic liability, and psychotic symptoms in subjects at high risk of developing schizophrenia. Biol Psychiat 2001; 49: 811-823
58. Lee FJ, Xue S, Pei L et al. Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor. Cell 2002; 111: 219-230
59. Leviel V, Gobert A, Guibert B. Direct observation of dopamine compartmentation in striatal nerve terminal by 'in vivo' measurement of the specific activity of released dopamine. Brain Res 1989; 499: 205-213
60. Mamo D, Kapur S, Shammi CM et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiat 2004; 161: 818-825
61. Mamo D, Graff A, Mizrahi R et al. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiat 2007; 164: 1411-1417
62. Manoach DS, Gollub RL, Benson ES et al. Schizophrenic subjects show aberrant fMRI activation of dorsolateral prefrontal cortex and basal ganglia during working memory performance. Biol Psychiat 2000; 48: 99-109
63. Meltzer HY, Matsubara S, Lee JC. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacology Bulletin 1989; 25: 390-392
64. Meyer-Lindenberg A, Miletich RS, Kohn PD et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 2002; 5: 267-271
65. Minuzzi L, Nomikas GG, Wade MR et al. Interaction between LSD and doparnine D2/3 binding sites in pig brain. Synapse 2005; 56: 198-204
66. Nordström AL, Farde L, Wiesel FA et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiat 1993; 33: 227-235
67. O'Connor WT. Functional neuroanatomy of the basal ganglia as studied by dual-probe microdialysis. Nucl Med Biol 1998; 25: 743-746
68. O'Connor WT. Functional neuroanatomy of the ventral striopallidal GABA pathway. New sites of interventin in the treatment of schizophrenia. J Neurosci Meth 2001; 109: 31-39
69. Oke AF, Adams RN. Elevated thalamic dopamine: possible link to sensory dysfunctions in schizophrenia. Schizophrenia Bulletin 1987; 13: 589-604
70. Oke AF, Putz C, Adams RN, Bird ED. Neuroleptic treatment is an unlikely cause of elevated dopamine in thalamus of schizophrenic subjects. Psychiat Res 1992; 45: 203-208
71. Okubo Y, Suhara T, Suzuki K et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 1997; 385: 634-636
72. Penit-Soria J, Audinat E, Crepel F. Excitation of rat prefrontal cortical neurons by dopamine: an in vitro electrophysiological study. Brain Res 1987; 425: 263-274
73. Petit-Taboue MC, Landeau B, Barre L et al. Parametric PET imaging of 5HT2A receptor distribution with 18F-setoperone in the normal human neocortex. J Nucl Med 1999; 40: 25-32
74. Preuss UW, Zetzsche T, Jager M et al. Thalamic volume in first-episode and chronic schizophrenic subjects: a volumetric MRI study. Schizophrenia Research 2005; 73: 91-101
75. Reith J, Benkelfat C, Sherwin A et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci USA 1994; 91: 11651-11654
76. Salgado-Pineda P, Baeza I, Perez-Gomez M et al. Sustained attention impairment correlates to gray matter decreases in first episode neuroleptic-naive schizophrenic patients. NeuroImage 2003; 19: 365-375
77. Seamans JK, Gorelova N, Durstewitz D, Yang CR. Bidirectional dopamine modulation of GABAergic inhibition in prefrontal cortical pyramidal neurons. J Neurosci 2001; 21: 3628-3638
78. Seamans JK, Yang CR. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 2004; 74: 1-58
79. Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975; 188: 1217-1219
80. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiat 2002; 47: 27-38
81. Slifstein M, Kolachana B, Simpson EH et al. COMT genotype predicts cortical-limbic D1 receptor availabi lity measured with [(11)C]NNC112 and PET. Mol Psychiat 2008
82. 11C]raclopride and PET in normal human subjects. Am J Psychiat 1997; 154: 490-496
83. Soares JC, Innis RB. Neurochemical brain imaging investigations of schizophrenia. Biol Psychiat 1999; 46: 600-615
84. Steriade M, Jones EG, MacCormick BA. Thalamus: organization and function. Amsterdam: Elsevier; 1997
85. Stone JM, Davis JM, Leucht S, Pilowsky LS. Cortical Dopamine D2/D3 Receptors Are a Common Site of Action for Antipsychotic Drugs - An Original Patient Data Meta-analysis of the SPECT and PET In Vivo Receptor Imaging Literature. Schizophrenia Bulletin 2008
86. Strungas S, Christensen JD, Holcomb JM, Garver DL. State-related thalamic changes during antipsychotic treatment in schizophrenia: preliminary observations. Psychiat Res 2003; 124: 121-124
87. Suhara T, Okubo Y, Yasuno F et al. Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch Gen Psychiat 2002; 59: 25-30
88. Taber MT, Baker GB, Fibiger HC. Glutamate receptor agonists decrease extracelluilar dopamine in the rat nucleus accumbens in vivo. Synapse 1996; 24: 165-172
89. Takahashi H, Higuchi M, Suhara T. The role of extrastriatal dopamine D2 receptors in schizophrenia. Biol Psychiat 2006; 59: 919-928
90. Tallerico T, Novak G, Liu IS, Ulpian C, Seeman P. Schizophrenia: elevated mRNA for dopamine D2(Longer) receptors in frontal cortex. Brain Res Mol Brain Res 2001; 87: 160-165
91. 11C]FLB 457. Int J Neuropsychopharmacol 2003; 6: 361-370
92. Tsukada H, Harada N, Nishiyama S et al. Ketamine decreased striatal [(11)C]raclopride binding with no alterations in static dopamine concentrations in the striatal extracellular fluid in the monkey brain: multiparametric PET studies combined with microdialysis analysis. Synapse 2000; 37: 95-103
93. Tuppurainen H, Kuikka J, Viinamaki H et al. Extrastriatal dopamine D 2/3 receptor density and distribution in drug-naive schizophrenic patients. Mol Psychiat 2003; 8: 453-455
94. Varty GB, Higgins GA. Dopamine agonist-induced hypothermia and disruption of prepulse inhibition: evidence for a role of D3 receptors? Behav Pharmacol 1998; 9: 445-455
95. Vernaleken I, Siessmeier T, Buchholz HG et al. High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia. Int J Neuropsychopharmacol 2004; 7: 421-430
96. 18F]-fluoro-L-DOPA-PET investigation. Hum Brain Mapp 2007; 28: 931-939
97. Vernaleken I, Kumakura Y, Buchholz HG et al. Baseline [(18)F]-FDOPA kinetics are predictive of haloperidol-induced changes in dopamine turnover and cognitive performance: A positron emission tomography study in healthy subjects. NeuroImage 2008; 40: 1222-1231
98. 18F]Fallypride Study. [Abstract] NeutoImage; in press
99. 18F]fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol 1997; 7: 9-24
100. 11C]raclopride PET study of a model psychosis in humans. J Psychiat Res 2000; 34: 35-43
101. Wan FJ, Swerdlow NR. Sensorimotor gating in rats is regulated by different dopamine-glutamate interactions in the nucleus accumbens core and shell subregions. Brain Res 1996; 722: 168-176
102. Weinberger DR, Laruelle M. Neurochemical and neuropharmacological imaging in schizophrenia. In: Davis KL, Charney DS, Coyle JT, Nemeroff C (eds). Neuropharmacology - the fifth generation of progress. Philadelphia: Lippincott, Williams, & Wilkins; 2001
103. Wilson CJ. Striatal D2 receptors and LTD: yes, but not where you thought they were. Neuron 2006; 50: 347-348
104. Winterer G. Prefrontal Dopamine Signaling in Schizophrenia - The Corticocentric Model. Pharmacopsychiatry 2007; 40: S45-S53
105. Xiberas X, Martinot JL, Mallet L et al. Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Brit J Psychiat 2001; 179: 503-508
106. Yang CR, Seamans JK. Dopamine D1 receptor actions in layers V-VI rat prefrontal cortex neurons in vitro: modulation of dendritic-somatic signal integration. J Neurosci 1996; 16: 1922-1935
107. Young KA, Randall PK, Wilcox RE. Startle and sensorimotor correlates of ventral thalamic doparnim and GABA in rodents. Neuroreport 1995; 6: 2495-2499
108. Young KA, Manaye KF, Liang C, Hicks PB, German DC. Reduced number of mediodorsal and anterior thalamic neurons in schizophrenia. Biol Psychiat 2000; 47: 944-953